FDA Requires Additional Information On DORIBAX For Treatment Of Hospital-Acquired Pneumonia Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced that the U.S. Food and Drug Administration (FDA) requires additional information before it will approve the company's New Drug Application (NDA) for DORIBAX(TM) (doripenem for injection) for the treatment of hospital-acquired pneumonia, also known as nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP).
Source: www.medicalnewstoday.comTelik's Proteasome Inhibitor Program Meets A Preclinical Development Milestone Telik, Inc. (Nasdaq: TELK) announced that its novel small molecule proteasome inhibitor program met a preclinical development milestone by demonstrating anticancer activity in preclinical models of human leukemia. The proteasome is an important cellular structure necessary for the growth and function of cancer cells and inhibition of the proteasome has been shown to promote cell cycle arrest and cancer cell death or apoptosis.
Source: www.medicalnewstoday.comBayer And Onyx Begin Enrollment In STORM Trial Studying Nexavar As Adjuvant Therapy For Patients With Liver Cancer Bayer
HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced the companies have begun enrolling patients in the STORM Sorafenib as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma trial.
Source: www.medicalnewstoday.comMajor Study Shows Quality-of-life Benefits From HRT A major international study of the effects of HRT use on quality of life has shown that HRT use can significantly improve well-being in women with menopausal symptoms such as hot flushes and night sweats. The results of the WISDOM study will be published on BMJ.com on Friday 22 August 2008 (note embargo details above). This study looked at
health-related quality of life in 5692
healthy women aged 50 - 69 in the UK, Australia and New Zealand.
Source: www.medicalnewstoday.comToronto Star Profiles Work Of Women's HIV/AIDS Advocacy Group In Namibia The Toronto Star on Wednesday profiled the work of the International Community of Women Living With HIV/AIDS in Namibia, which aims to improve support, information and services available for HIV-positive women in the country. The group also works to increase HIV-positive women's influence and input on policy development in Namibia.
Source: www.medicalnewstoday.comThe New MagNA Pure LC 2.0 System: New Design And Improved Performance Meet A Proven Nucleic Acid Isolation Technology A fast, flexible, and reliable isolation of pure nucleic acids from various sample materials is crucial for sensitive molecular analysis by PCR, RT-PCR, sequencing, arrays etc. In addition, automation of nucleic acid isolation is becoming increasingly important for reproducibility and to reduce experimental error. During the last years, demands regarding hardware design, software, and operating system have been increasing. The new MagNA Pure LC 2.
Source: www.medicalnewstoday.comHead-to-Head Study Showed Prasugrel Statistically Superior To Clopidogrel In Reducing Recurrent Cardiovascular Events A new, pre-specified analysis of the landmark Phase III head-to-head TRITON-TIMI 38 study showed patients who took prasugrel for acute coronary syndromes (ACS) managed with an artery-opening procedure known as percutaneous coronary intervention (PCI) and had survived their first cardiov
Source: www.medicalnewstoday.com
# posted by Network @ 8:00 AM
